What Is a Rare Disease — and Why Does Speed Matter?

A rare disease is any condition that affects fewer than 200,000 people in the United States. But the word "rare" can be deeply misleading. There are over 10,000 known rare diseases worldwide, and collectively they affect an estimated 400 million people globally — roughly 30 million in the U.S. alone. That means about 1 in 10 Americans is living with a rare disease, whether they know it or not.

For the families who receive a rare disease diagnosis, the experience is often defined by a painful paradox: the condition may be rare, but the suffering is not. Many families spend years on what's known as the "diagnostic odyssey" — visiting specialist after specialist, undergoing test after test, before finally receiving a name for what their loved one is facing. And even once a diagnosis arrives, the next question is often the hardest: now what?

The Scale of the Problem

Approximately 80% of rare diseases are genetic in origin, meaning they are caused by changes — sometimes just a single letter — in a person's DNA. Some of these conditions are apparent at birth. Others don't manifest symptoms until childhood, adolescence, or even adulthood. And because each individual condition affects so few people, the traditional pharmaceutical industry has historically had little financial incentive to develop treatments.

The numbers tell a sobering story. Of the more than 10,000 identified rare diseases, fewer than 5% have an FDA-approved treatment. That leaves the vast majority of rare disease patients and their families with no approved therapeutic options — relying instead on symptom management, off-label drug use, or simply waiting and hoping that research catches up.

Why the Traditional Timeline Fails Families

In conventional drug development, the journey from laboratory discovery to approved treatment takes an average of 10 to 15 years and costs upward of $2 billion. The process moves through preclinical research, animal testing, and three phases of clinical trials before a drug can reach patients. For common diseases with large patient populations, this timeline — while painfully slow — is at least supported by significant commercial investment.

For rare diseases, the math simply doesn't work. The patient populations are too small to attract large-scale pharmaceutical investment, and the traditional timeline is too long for families watching their loved ones decline. Children grow. Symptoms progress. Windows of opportunity close.

This is the fundamental problem that drives everything we do at RareLabs: time is life, and the traditional research timeline is not built for families who need answers now.

A Different Approach

Modern science has given us tools that didn't exist even a decade ago. Nobel Prize-winning stem cell technology allows us to take a patient's own blood or skin cells and reprogram them into the exact type of cell affected by their disease. CRISPR gene editing lets us create "corrected" versions of those cells for direct comparison. High-throughput screening systems can test thousands of existing FDA-approved drugs against a patient's disease model in a matter of weeks.

At RareLabs, we use these tools to compress the research timeline from years to months. We don't wait for the traditional process. We build personalized disease models, test multiple treatment approaches simultaneously, and deliver clear, honest results to families and their medical teams.

Our goal is not to promise a cure. Our goal is to provide answers — quickly and clearly — about what might help and what won't, so families and their doctors can make better, more informed decisions.

Every Day Matters

For families living with a rare disease, the urgency is not abstract. It's felt in every doctor's appointment, every new symptom, every birthday that passes without progress. The rare disease community doesn't have the luxury of patience.

That's why speed matters. Not reckless speed — but purposeful, scientifically rigorous speed. The kind of speed that comes from using the best available tools, pursuing multiple paths at once, and refusing to accept that "rare" means "forgotten."

Time is life. And the search for answers can't wait.